Similarly, the National Cancer Institute is also conducting a phase II trial (NCT04548752) comparing the use of Olaparib alone versus Olaparib and Pembrolizumab in metastatic germline BRCA1/2‐mutated pancreatic cancer.295. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.